Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study

Br J Haematol. 2018 Apr;181(2):259-261. doi: 10.1111/bjh.14540. Epub 2017 Feb 21.

Authors

Anthony R Mato¹, Colleen Timlin¹, Chaitra Ujjani², Alan Skarbnik³, Christina Howlett³, Rahul Banerjee¹, Chadi Nabhan⁴, Stephen J Schuster¹

Affiliations

¹ Center for CLL, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
² Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Chicago, DC, USA.
³ John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
⁴ University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.

PMID: 28220935
DOI: 10.1111/bjh.14540

No abstract available

Keywords: Bruton's tyrosine kinase; Ibrutinib; chronic lymphocytic leukaemia.

Publication types

Clinical Trial
Comparative Study
Letter
Multicenter Study

MeSH terms

Adenine / analogs & derivatives
Disease-Free Survival
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / mortality*
Male
Piperidines
Pyrazoles / administration & dosage*
Pyrimidines / administration & dosage*
Retrospective Studies
Survival Rate

Substances

Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Adenine